What are the therapeutic effects of fosfomycin trometamol powder?

Phosphomycin trometamol granules are an oral antibiotic formulation primarily used for the treatment of uncomplicated lower urinary tract infections (UTIs), such as acute cystitis, in adults. The active ingredient—phosphomycin—is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by irreversibly binding to the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), thereby blocking the first step in peptidoglycan biosynthesis. This unique mechanism confers activity against a broad spectrum of common uropathogens, including Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus mirabilis, many of which may be resistant to other antibiotics.

The trometamol salt enhances oral bioavailability and ensures rapid absorption, with peak urinary concentrations achieved within 2–4 hours after a single oral dose. Due to its pharmacokinetic profile—high urinary excretion (>90% unchanged) and low systemic exposure—the drug achieves therapeutic concentrations specifically in the urinary tract while minimizing systemic side effects. It is not indicated for upper UTIs (e.g., pyelonephritis), complicated UTIs, or systemic infections.

Clinical guidelines, including those from the European Association of Urology (EAU) and the Infectious Diseases Society of America (IDSA), recognize phosphomycin trometamol as a first-line option for empiric treatment of acute uncomplicated cystitis, particularly in regions with high rates of fluoroquinolone or trimethoprim-sulfamethoxazole resistance. Its single-dose regimen improves adherence and reduces selection pressure for antimicrobial resistance. Common adverse effects are generally mild and gastrointestinal in nature (e.g., diarrhea, nausea, dyspepsia); serious hypersensitivity reactions are rare.